Available Technologies
# of Displayed Technologies: 4 / 4
Applied Category Filter (Click To Remove): Other
Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 —
A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
- College: College of Medicine (COM)
- Inventors: Williams, Terence; Lee, Robert
- Licensing Officer: He, Panqing
Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
- College: College of Engineering (COE)
- Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
- Licensing Officer: He, Panqing
Development of STAT3 dimerization inhibitors for cancers
TS-037569 —
The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
- Licensing Officer: He, Panqing
LNA Inhibitor Cocktail Therapy for Lupus
TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.
Systemic lupus erythematosus (SLE) is an orphan disease affecting approximately 5 in every 10,000 individuals. Despite its rare prevalence, this lifelong autoimmune disease has few effective targeted therapies. Current treatments are palliative using anti-inflammatory drugs or broad spectrum immun…
- College: College of Medicine (COM)
- Inventors: Jarjour, Wael; Valiente, Giancarlo; Young, Nicholas
- Licensing Officer: He, Panqing
